2 October 2025 From stalled drug approvals to suspended patent investigations, US rightsholders face mounting uncertainty during the federal freeze.
2 October 2025
2 October 2025
30 September 2025
30 September 2025
Latest Features
Americas
In the second of a two-part series, Mercedes Meyer of Banner Witcoff and Brandon Phemester of Novavax delve into the real reasons why medicine costs more in the US.
Americas
In the first of a two-part series, Mercedes Meyer of Banner Witcoff and Brandon Phemester of Novavax explore how legislative, judicial, and executive policies have dramatically altered the risks for drug innovation.
Biotechnology
Erik Viik of Papula-Nevinpat looks at the dynamics that international applicants need to be aware of to secure and manage their patent rights across the region.
Americas
With growing legislation, research and demand for medical use, cannabis presents an economic opportunity for the Caribbean—but IP rights in the region have some way to go, write Keesha Fleming Lake of Keesha Fleming Lake, and Rachael Lodge Corrie of Foga Daley.
Americas
From setting a clear overall strategy to drafting high-quality claims, Christopher Wheeler and Gerald Murphy of Birch, Stewart, Kolasch & Birch explain how to reduce patent prosecution expenditure and obtain better IP protection.
Asia
Hui Zhuang of CCPIT Patent and Trademark Law Office discusses several strategies to increase the chance of pharmaceutical or food trademarks that include ingredients being registered.
Americas
A procedural change at the Patent Trial and Appeal Board offers petitioners a valuable tool to push back against Fintiv-based discretionary denial, writes Taylor Stemler of Merchant & Gould.
Americas
A patent fee structure being mooted in the US could hurt the innovation economy, especially in industries like biotech and pharma—and will face backlash from businesses, writes Paul Hunter of Foley.
More News
29 September 2025 Complaint alleges the pair used Massachusetts company’s patented mRNA TALEN gene-editing technology without permission in multi-billion-dollar cancer therapy deals.
26 September 2025 Sweeping tariffs send shockwaves through the pharma sector, as experts warn of consumer detriment and supply chain risks.
25 September 2025 A new survey from LSIPR reveals that European patent practitioners are grappling with client budget constraints and fast-evolving technologies, with most expecting patenting challenges to increase over the next five years.
25 September 2025 The General Court has handed a win to generic drug makers including Teva and Mylan in the battle over multiple sclerosis drug Tecfidera.
25 September 2025 The firm’s Technology & Engineering team will be expanded with an expert in patent drafting, prosecution and opposition/defence work across AI, digital health and medical devices.
24 September 2025 A biotech firm specialising in mRNA therapies alleges AbbVie’s $2.1 billion Capstan purchase was built on stolen lipid nanoparticle trade secrets.
23 September 2025 As John Squires is confirmed as the US Patent and Trademark Office's new director, Sarah Speight gathers reaction, and asks: what would you ask the US’ chief IP executive?
Get up-to-date information on all our publications and events
Get critical life sciences news direct to your inbox